Skip to content
Paragon Biosciences LLC
  • About Us
  • Our Approach
  • Portfolio
  • Leadership
  • Careers
  • Contact Us
  • News Room

epidermolysis bullosa

3 items

  • December 16, 2019

    Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science

    – Acquisition complements and expands Castle Creek [...]

  • June 25, 2018

    Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment

    New multi-center Phase 1 study expected to [...]

  • May 16, 2018

    Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa

    PARSIPPANY, N.J., May 16, 2018 – Castle Creek [...]

© 2026 Paragon Biosciences LLC | Privacy Policy | Terms of Use

330 N Wabash Avenue, Suite 3500, Chicago, IL 60611 |

© 2026 Paragon Biosciences LLC | Privacy Policy | Terms of Use

330 N Wabash Avenue, Suite 3500, Chicago, IL 60611

© 2026 Paragon Biosciences LLC
Privacy Policy | Terms of Use

330 N Wabash Avenue, Suite 3500
Chicago, IL 60611

Page load link
Go to Top